What is the intrinsic value of STOK?
As of 2025-06-22, the Intrinsic Value of Stoke Therapeutics Inc (STOK) is
4.60 USD. This STOK valuation is based on the model Peter Lynch Fair Value.
With the current market price of 11.58 USD, the upside of Stoke Therapeutics Inc is
-60.24%.
Is STOK undervalued or overvalued?
Based on its market price of 11.58 USD and our intrinsic valuation, Stoke Therapeutics Inc (STOK) is overvalued by 60.24%.
STOK Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
(363.44) - (23.20) |
(45.51) |
-493.0% |
| DCF (Growth 10y) |
(22.39) - (313.30) |
(41.66) |
-459.7% |
| DCF (EBITDA 5y) |
(18.14) - (22.89) |
(1,234.50) |
-123450.0% |
| DCF (EBITDA 10y) |
(18.67) - (25.53) |
(1,234.50) |
-123450.0% |
| Fair Value |
4.60 - 4.60 |
4.60 |
-60.24% |
| P/E |
19.11 - 36.22 |
26.66 |
130.2% |
| EV/EBITDA |
14.31 - 27.28 |
19.44 |
67.9% |
| EPV |
(12.44) - (21.60) |
(17.02) |
-247.0% |
| DDM - Stable |
6.65 - 40.72 |
23.68 |
104.5% |
| DDM - Multi |
(8.55) - (44.12) |
(14.69) |
-226.9% |
STOK Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
632.27 |
| Beta |
1.79 |
| Outstanding shares (mil) |
54.60 |
| Enterprise Value (mil) |
357.45 |
| Market risk premium |
4.60% |
| Cost of Equity |
9.86% |
| Cost of Debt |
5.00% |
| WACC |
6.77% |